JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.140, ss.151-157, 2014 (SCI İndekslerine Giren Dergi)
The development of brain metastases (BMs) was associated with poor prognosis in melanoma patients. Patients with BMs have a median survival of < 6 months. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %. Our aim was to identify factors predicting development of BMs and survival.